• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用MONOLIX软件估算HIV患者中沙奎那韦的群体药代动力学参数。

Estimation of population pharmacokinetic parameters of saquinavir in HIV patients with the MONOLIX software.

作者信息

Lavielle Marc, Mentré France

机构信息

Department of Mathematics, University Paris 5; University Paris 11, Orsay, France.

出版信息

J Pharmacokinet Pharmacodyn. 2007 Apr;34(2):229-49. doi: 10.1007/s10928-006-9043-z. Epub 2007 Jan 9.

DOI:10.1007/s10928-006-9043-z
PMID:17211713
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1974848/
Abstract

In nonlinear mixed-effects models, estimation methods based on a linearization of the likelihood are widely used although they have several methodological drawbacks. Kuhn and Lavielle (Comput. Statist. Data Anal. 49:1020-1038 (2005)) developed an estimation method which combines the SAEM (Stochastic Approximation EM) algorithm, with a MCMC (Markov Chain Monte Carlo) procedure for maximum likelihood estimation in nonlinear mixed-effects models without linearization. This method is implemented in the Matlab software MONOLIX which is available at http://www.math.u-psud.fr/~lavielle/monolix/logiciels. In this paper we apply MONOLIX to the analysis of the pharmacokinetics of saquinavir, a protease inhibitor, from concentrations measured after single dose administration in 100 HIV patients, some with advance disease. We also illustrate how to use MONOLIX to build the covariate model using the Bayesian Information Criterion. Saquinavir oral clearance (CL/F) was estimated to be 1.26 L/h and to increase with body mass index, the inter-patient variability for CL/F being 120%. Several methodological developments are ongoing to extend SAEM which is a very promising estimation method for population pharmacockinetic/pharmacodynamic analyses.

摘要

在非线性混合效应模型中,基于似然线性化的估计方法虽存在若干方法学缺陷,但仍被广泛使用。库恩和拉维耶(《计算统计学与数据分析》49:1020 - 1038 (2005))开发了一种估计方法,该方法将SAEM(随机近似期望最大化)算法与MCMC(马尔可夫链蒙特卡罗)程序相结合,用于非线性混合效应模型的最大似然估计,无需进行线性化。此方法在Matlab软件MONOLIX中实现,该软件可从http://www.math.u - psud.fr/~lavielle/monolix/logiciels获取。在本文中,我们将MONOLIX应用于分析沙奎那韦(一种蛋白酶抑制剂)的药代动力学,数据来自100名HIV患者单剂量给药后的血药浓度测量值,其中部分患者患有晚期疾病。我们还说明了如何使用MONOLIX,通过贝叶斯信息准则构建协变量模型。沙奎那韦的口服清除率(CL/F)估计为1. .26 L/h,且随体重指数增加,CL/F的患者间变异性为120%。目前正在进行多项方法学改进,以扩展SAEM,SAEM是群体药代动力学/药效学分析中一种非常有前景的估计方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1924/1974848/b26d1379455d/halms156907f8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1924/1974848/4e667627c11e/halms156907f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1924/1974848/11d6473027cd/halms156907f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1924/1974848/3e028b2a5277/halms156907f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1924/1974848/5bf6872bf185/halms156907f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1924/1974848/2bc003daafec/halms156907f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1924/1974848/8dfa1809b99c/halms156907f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1924/1974848/0f9be3ce2812/halms156907f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1924/1974848/b26d1379455d/halms156907f8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1924/1974848/4e667627c11e/halms156907f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1924/1974848/11d6473027cd/halms156907f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1924/1974848/3e028b2a5277/halms156907f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1924/1974848/5bf6872bf185/halms156907f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1924/1974848/2bc003daafec/halms156907f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1924/1974848/8dfa1809b99c/halms156907f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1924/1974848/0f9be3ce2812/halms156907f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1924/1974848/b26d1379455d/halms156907f8.jpg

相似文献

1
Estimation of population pharmacokinetic parameters of saquinavir in HIV patients with the MONOLIX software.使用MONOLIX软件估算HIV患者中沙奎那韦的群体药代动力学参数。
J Pharmacokinet Pharmacodyn. 2007 Apr;34(2):229-49. doi: 10.1007/s10928-006-9043-z. Epub 2007 Jan 9.
2
Fisher information matrix for nonlinear mixed effects multiple response models: evaluation of the appropriateness of the first order linearization using a pharmacokinetic/pharmacodynamic model.非线性混合效应多响应模型的费希尔信息矩阵:使用药代动力学/药效学模型评估一阶线性化的适用性
Stat Med. 2009 Jun 30;28(14):1940-56. doi: 10.1002/sim.3573.
3
Data cloning: easy maximum likelihood estimation for complex ecological models using Bayesian Markov chain Monte Carlo methods.数据克隆:使用贝叶斯马尔可夫链蒙特卡罗方法对复杂生态模型进行简便的最大似然估计。
Ecol Lett. 2007 Jul;10(7):551-63. doi: 10.1111/j.1461-0248.2007.01047.x.
4
The SAEM algorithm for group comparison tests in longitudinal data analysis based on non-linear mixed-effects model.基于非线性混合效应模型的纵向数据分析中用于组间比较检验的SAEM算法。
Stat Med. 2007 Nov 30;26(27):4860-75. doi: 10.1002/sim.2950.
5
The pharmacokinetics, safety and efficacy of boosted saquinavir tablets in HIV type-1-infected pregnant women.增强型沙奎那韦片在HIV-1感染孕妇中的药代动力学、安全性和疗效。
Antivir Ther. 2009;14(3):443-50.
6
Limited-sampling strategy for the prediction of boosted hard-gel saquinavir exposure at a dosage of 1000/100 mg twice daily in human immunodeficiency virus-infected individuals.在人类免疫缺陷病毒感染个体中,采用有限采样策略预测每日两次服用1000/100毫克剂量的硬明胶型沙奎那韦的暴露量。
Ther Drug Monit. 2007 Jun;29(3):361-7. doi: 10.1097/FTD.0b013e3180683b25.
7
Inhibitory quotient as a prognostic factor of response to a salvage antiretroviral therapy containing ritonavir-boosted saquinavir. The CIVSA Study.抑制商数作为含利托那韦增强型沙奎那韦挽救性抗逆转录病毒治疗反应的预后因素。CIVSA研究。
HIV Med. 2007 May;8(4):226-33. doi: 10.1111/j.1468-1293.2007.00464.x.
8
Statistical models for autocorrelated count data.自相关计数数据的统计模型。
Stat Med. 2006 Apr 30;25(8):1413-30. doi: 10.1002/sim.2274.
9
Exploratory Bayesian model selection for serial genetics data.用于序列遗传学数据的探索性贝叶斯模型选择
Biometrics. 2005 Jun;61(2):591-9. doi: 10.1111/j.1541-0420.2005.040417.x.
10
Modeling attainment of steady state of drug concentration in plasma by means of a Bayesian approach using MCMC methods.采用马尔可夫链蒙特卡罗(MCMC)方法,通过贝叶斯方法对血浆中药物浓度的稳态达到情况进行建模。
Pharm Stat. 2008 Jan-Mar;7(1):36-41. doi: 10.1002/pst.263.

引用本文的文献

1
Baseline Drug Clearance Predicts Outcomes in Children With Inflammatory Bowel Disease Treated With Vedolizumab: Results From the VedoKids Prospective Multicentre Study.基线药物清除率可预测接受维多珠单抗治疗的炎症性肠病儿童的预后:VedoKids前瞻性多中心研究结果
Aliment Pharmacol Ther. 2025 Mar;61(6):1000-1010. doi: 10.1111/apt.18484. Epub 2025 Jan 15.
2
Model-informed drug discovery and development approaches to inform clinical trial design and regulatory decisions: A primer for the MENA region.用于指导临床试验设计和监管决策的模型驱动药物发现与开发方法:中东和北非地区入门指南
Saudi Pharm J. 2024 Dec;32(12):102207. doi: 10.1016/j.jsps.2024.102207. Epub 2024 Nov 27.
3

本文引用的文献

1
Non-linear mixed effects modeling - from methodology and software development to driving implementation in drug development science.非线性混合效应建模——从方法学与软件开发到推动药物研发科学中的应用
J Pharmacokinet Pharmacodyn. 2005 Apr;32(2):161-83. doi: 10.1007/s10928-005-0062-y. Epub 2005 Nov 7.
2
Optimization of individual and population designs using Splus.使用Splus对个体和群体设计进行优化。
J Pharmacokinet Pharmacodyn. 2003 Dec;30(6):417-43. doi: 10.1023/b:jopa.0000013000.59346.9a.
3
Enhanced saquinavir exposure in human immunodeficiency virus type 1-infected patients with diarrhea and/or wasting syndrome.
Influenza virus shedding and symptoms: Dynamics and implications from a multiseason household transmission study.
流感病毒排出与症状:一项多季节家庭传播研究的动态变化及影响
PNAS Nexus. 2024 Aug 21;3(9):pgae338. doi: 10.1093/pnasnexus/pgae338. eCollection 2024 Sep.
4
Exploring carbon source related localization and phosphorylation in the Snf1/Mig1 network using population and single cell-based approaches.使用群体和单细胞方法探索Snf1/Mig1网络中与碳源相关的定位和磷酸化。
Microb Cell. 2024 May 16;11:143-154. doi: 10.15698/mic2024.05.822. eCollection 2024.
5
Public Health Impact of Paxlovid as Treatment for COVID-19, United States.辉瑞公司研发的新冠病毒治疗药物 Paxlovid 对公共卫生的影响,美国。
Emerg Infect Dis. 2024 Feb;30(2):262-269. doi: 10.3201/eid3002.230835. Epub 2024 Jan 5.
6
High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trials.高单克隆中和滴度降低了抗体介导预防试验中的突破性 HIV-1 病毒载量。
Nat Commun. 2023 Dec 14;14(1):8299. doi: 10.1038/s41467-023-43384-y.
7
Practical Understanding of Cancer Model Identifiability in Clinical Applications.临床应用中癌症模型可识别性的实践理解
Life (Basel). 2023 Feb 1;13(2):410. doi: 10.3390/life13020410.
8
Population Pharmacokinetics of Isavuconazole in Critical Care Patients with COVID-19-Associated Pulmonary Aspergillosis and Monte Carlo Simulations of High Off-Label Doses.艾沙康唑在新冠病毒相关肺曲霉病重症监护患者中的群体药代动力学及高超说明书剂量的蒙特卡洛模拟
J Fungi (Basel). 2023 Feb 6;9(2):211. doi: 10.3390/jof9020211.
9
Modeling recapitulates the heterogeneous outcomes of SARS-CoV-2 infection and quantifies the differences in the innate immune and CD8 T-cell responses between patients experiencing mild and severe symptoms.建模再现了 SARS-CoV-2 感染的异质结果,并量化了轻症和重症患者之间固有免疫和 CD8 T 细胞反应的差异。
PLoS Pathog. 2022 Jun 27;18(6):e1010630. doi: 10.1371/journal.ppat.1010630. eCollection 2022 Jun.
10
Assessment of Micafungin Dosage Regimens in Patients with Cancer Using Pharmacokinetic/Pharmacodynamic Modeling and Monte Carlo Simulation.使用药代动力学/药效学模型和蒙特卡洛模拟评估癌症患者的米卡芬净给药方案。
Antibiotics (Basel). 2021 Nov 8;10(11):1363. doi: 10.3390/antibiotics10111363.
在感染人类免疫缺陷病毒1型且患有腹泻和/或消瘦综合征的患者中,沙奎那韦的暴露量增加。
Antimicrob Agents Chemother. 2004 Feb;48(2):538-45. doi: 10.1128/AAC.48.2.538-545.2004.
4
Efficient screening of covariates in population models using Wald's approximation to the likelihood ratio test.使用似然比检验的Wald近似法在总体模型中有效筛选协变量。
J Pharmacokinet Pharmacodyn. 2001 Jun;28(3):253-75. doi: 10.1023/a:1011579109640.
5
Correcting for measurement error in individual-level covariates in nonlinear mixed effects models.校正非线性混合效应模型中个体水平协变量的测量误差。
Biometrics. 2000 Jun;56(2):368-75. doi: 10.1111/j.0006-341x.2000.00368.x.
6
Automated covariate model building within NONMEM.NONMEM 中的自动协变量模型构建。
Pharm Res. 1998 Sep;15(9):1463-8. doi: 10.1023/a:1011970125687.
7
Variance components testing in the longitudinal mixed effects model.纵向混合效应模型中的方差成分检验
Biometrics. 1994 Dec;50(4):1171-7.
8
A two-step iterative algorithm for estimation in nonlinear mixed-effect models with an evaluation in population pharmacokinetics.一种用于非线性混合效应模型估计的两步迭代算法及其在群体药代动力学中的评估。
J Biopharm Stat. 1995 Jul;5(2):141-58. doi: 10.1080/10543409508835104.
9
Applications of multiple imputation to the analysis of censored regression data.多重填补在删失回归数据分析中的应用。
Biometrics. 1991 Dec;47(4):1297-309.
10
Estimation of population characteristics of pharmacokinetic parameters from routine clinical data.根据常规临床数据估算药代动力学参数的群体特征。
J Pharmacokinet Biopharm. 1977 Oct;5(5):445-79. doi: 10.1007/BF01061728.